UBS Raises Estimates on CVS (CVS)

UBS reported on Thursday that it has raised estimates on drugstore chain, CVS Caremark Corporation (CVS).

The firm has increased its estimates for CVS, and had given the company a $60 price target. This price target suggests a 12% upside from the stock’s current price of $52.90.

Analysts have raised estimates on the company based on the potential benefits to the company from the health reform in 2014-2015.

CVS shares were mostly flat during premarket trading Thursday. The stock has increased 16% in the past year.

The Bottom Line
Shares of CVS Caremark Corporation (CVS) have a 1.70% yield, based on Wednesday’s closing price of $52.90.

CVS Caremark Corporation (CVS) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here